Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec

According to the Federal Register, the FDA announced it will hold a public meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee to discuss a new drug application from Replimune, Incorporated. The company is seeking approval for an experimental cellular therapy. The agency is also opening a public docket to accept written comments from the public on the application.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton